WallStreetZenWallStreetZen

NASDAQ: GRFS
Grifols Sa Stock

$9.69+0.03 (+0.31%)
Updated Nov 30, 2023
GRFS Price
$9.69
Fair Value Price
$12.59
Market Cap
$6.66B
52 Week Low
$6.50
52 Week High
$10.97
P/E
28.75x
P/B
1x
P/S
0.91x
PEG
0.39x
Dividend Yield
N/A
Revenue
$6.59B
Earnings
$221.57M
Gross Margin
36.8%
Operating Margin
13.11%
Profit Margin
3.4%
Debt to Equity
2.13
Operating Cash Flow
-$12M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GRFS Overview

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Zen Score

Industry Average (42)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GRFS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GRFS ($9.69) is undervalued by 23.02% relative to our estimate of its Fair Value price of $12.59 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GRFS ($9.69) is significantly undervalued by 23.02% relative to our estimate of its Fair Value price of $12.59 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GRFS ($9.69) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more GRFS due diligence checks available for Premium users.

Be the first to know about important GRFS news, forecast changes, insider trades & much more!

GRFS News

Valuation

GRFS fair value

Fair Value of GRFS stock based on Discounted Cash Flow (DCF)
Price
$9.69
Fair Value
$12.59
Undervalued by
23.02%
GRFS ($9.69) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GRFS ($9.69) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GRFS ($9.69) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GRFS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
28.75x
Industry
43.24x
Market
29.24x
GRFS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GRFS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

GRFS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1x
Industry
5.34x
GRFS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GRFS price to earnings growth (PEG)

For valuing profitable companies with growth potential
GRFS is good value based... subscribe to Premium to read more.
PEG Value Valuation

GRFS's financial health

Profit margin

Revenue
$6.5B
Net Income
$221.6M
Profit Margin
3.4%
GRFS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GRFS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$22.9B
Liabilities
$13.9B
Debt to equity
2.13
GRFS's short-term assets ($5.06B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRFS's long-term liabilities ($12.09B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRFS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GRFS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$11.6M
Investing
-$2.1B
Financing
-$184.6M
GRFS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GRFS vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
GRFS$6.66B+0.31%28.75x1.00x
OGN$2.89B-0.79%4.92x-4.91x
AMRN$319.28M+4.27%-6.52x0.58x
SCLX$194.93M-10.71%-1.06x-1.20x
BIIB$33.92B+0.87%23.06x2.34x

Grifols Sa Stock FAQ

What is Grifols Sa's quote symbol?

(NASDAQ: GRFS) Grifols Sa trades on the NASDAQ under the ticker symbol GRFS. Grifols Sa stock quotes can also be displayed as NASDAQ: GRFS.

If you're new to stock investing, here's how to buy Grifols Sa stock.

What is the 52 week high and low for Grifols Sa (NASDAQ: GRFS)?

(NASDAQ: GRFS) Grifols Sa's 52-week high was $10.97, and its 52-week low was $6.50. It is currently -11.63% from its 52-week high and 49.08% from its 52-week low.

How much is Grifols Sa stock worth today?

(NASDAQ: GRFS) Grifols Sa currently has 687,554,908 outstanding shares. With Grifols Sa stock trading at $9.69 per share, the total value of Grifols Sa stock (market capitalization) is $6.66B.

Grifols Sa stock was originally listed at a price of $7.65 in Jun 2, 2011. If you had invested in Grifols Sa stock at $7.65, your return over the last 12 years would have been 26.67%, for an annualized return of 1.99% (not including any dividends or dividend reinvestments).

How much is Grifols Sa's stock price per share?

(NASDAQ: GRFS) Grifols Sa stock price per share is $9.69 today (as of Nov 30, 2023).

What is Grifols Sa's Market Cap?

(NASDAQ: GRFS) Grifols Sa's market cap is $6.66B, as of Dec 2, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Grifols Sa's market cap is calculated by multiplying GRFS's current stock price of $9.69 by GRFS's total outstanding shares of 687,554,908.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.